

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017**SECTION 1. IDENTIFICATION**

Product name : ALECENSA® Capsules (150 mg)

Product code : RO542-4802/F16

Common name(s), syno- : Alectinib Capsules 150 mg
nym(s) of the substance BS10767**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : DNA Way 1
94080 South San Francisco
CA
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

Emergency telephone num- : US Chemtrec phone (800)-424-9300
ber**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Skin irritation : Category 2

Serious eye damage : Category 1

Germ cell mutagenicity : Category 2

Carcinogenicity : Category 2

Reproductive toxicity : Category 2

Specific target organ toxicity : Category 2
- repeated exposure**GHS label elements**

Hazard pictograms :



Signal Word : Danger

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

Hazard Statements : H315 Causes skin irritation.
H318 Causes serious eye damage.
H341 Suspected of causing genetic defects.
H351 Suspected of causing cancer.
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P362 Take off contaminated clothing and wash before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Alectinib hydrochloride	1256589-74-8	40.3
Cellulose, 2-hydroxypropyl methyl ether	9004-65-3	19.2
Sulfuric acid monododecyl ester sodium salt (1:1)	151-21-3	18.8
Cellulose, carboxymethyl ether, calcium salt	9050-04-8	10.8
Lactose-monohydrate	10039-26-6	8.4

ALECENSA® Capsules (150 mg)
Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

Titanium oxide (TiO ₂)	13463-67-7	1.1
Octadecanoic acid, magnesium salt (2:1)	557-04-0	0.4
non hazardous compounds	Not Assigned	1.0

SECTION 4. FIRST AID MEASURES

- General advice : Move out of dangerous area.
Consult a physician.
Show this material safety data sheet to the doctor in attendance.
Do not leave the victim unattended.
- If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.
- In case of skin contact : If skin irritation persists, call a physician.
If on skin, rinse well with water.
If on clothes, remove clothes.
- In case of eye contact : Small amounts splashed into eyes can cause irreversible tissue damage and blindness.
In the case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
Continue rinsing eyes during transport to hospital.
Remove contact lenses.
Protect unharmed eye.
Keep eye wide open while rinsing.
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.
Do NOT induce vomiting.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Take victim immediately to hospital.
Rinse mouth with water.
- Most important symptoms and effects, both acute and delayed : Causes skin irritation.
Causes serious eye damage.
Suspected of causing genetic defects.
Suspected of causing cancer.
Suspected of damaging fertility. Suspected of damaging the unborn child.
May cause damage to organs through prolonged or repeated exposure.
- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local

ALECENSA® Capsules (150 mg)

Version 1.2	Revision Date: 01-16-2020	Date of last issue: 07-27-2018 Date of first issue: 06-10-2017
----------------	------------------------------	---

circumstances and the surrounding environment.

- Unsuitable extinguishing media : High volume water jet
- Specific hazards during fire fighting : Do not allow run-off from fire fighting to enter drains or water courses.
- Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:
Carbon oxides
Nitrogen oxides (NOx)
Gaseous hydrogen chloride (HCl).
- Further information : Collect contaminated fire extinguishing water separately. This must not be discharged into drains.
Fire residues and contaminated fire extinguishing water must be disposed of in accordance with local regulations.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Avoid exposure
Use personal protective equipment.
Avoid dust formation.
Avoid breathing dust.
- Environmental precautions : Prevent product from entering drains.
Prevent further leakage or spillage if safe to do so.
If the product contaminates rivers and lakes or drains inform respective authorities.
- Methods and materials for containment and cleaning up : Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

- Advice on protection against fire and explosion : Avoid dust formation.
Provide appropriate exhaust ventilation at places where dust is formed.
- Advice on safe handling : Avoid formation of respirable particles.
Do not breathe vapors/dust.
Avoid exposure - obtain special instructions before use.
Avoid contact with skin and eyes.
For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.
Dispose of rinse water in accordance with local and national regulations.
- Conditions for safe storage : Keep container tightly closed in a dry and well-ventilated

ALECENSA® Capsules (150 mg)
Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

place.

Containers which are opened must be carefully resealed and kept upright to prevent leakage.

Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions : See label, package insert or internal guidelines

Storage temperature : to 30 °C
Protect against light.
Protect from moisture.

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Blister packages, Stainless steel, glass

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Alectinib hydrochloride The value is given in analogy to the following substances: Alectinib	1256589-74-8	IOEL	0.001 mg/m ³	Roche Industrial Hygiene Committee (RIHC)
Titanium oxide (TiO ₂)	13463-67-7	TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (Total dust)	10 mg/m ³	OSHA P0
		TWA	10 mg/m ³ (Titanium dioxide)	ACGIH
Octadecanoic acid, magnesium salt (2:1)	557-04-0	TWA (Inhalable fraction)	10 mg/m ³	ACGIH
		TWA (Respirable fraction)	3 mg/m ³	ACGIH

Predicted No Effect Concentration (PNEC):

Substance name	Environmental Compartment	Value
Alectinib hydrochloride	Surface waters	0.0133 mg/l
	Remarks: Based on chronic data	
Sulfuric acid monododecyl ester sodium salt (1:1)	Fresh water	0.176 mg/l
	Sea water	0.0176 mg/l
	Fresh water sediment	6.97 mg/kg
	Sea sediment	0.697 mg/kg
	Soil	1.29 mg/kg

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017**Personal protective equipment**

Respiratory protection : In the case of dust or aerosol formation use respirator with an approved filter.
Effective dust mask

Hand protection

Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.

Eye protection : Eye wash bottle with pure water
Tightly fitting safety goggles
Wear face-shield and protective suit for abnormal processing problems.

Skin and body protection : Choose body protection according to the amount and concentration of the dangerous substance at the work place.

Protective measures : Instruction of employees recommended

Hygiene measures : When using do not eat or drink.
When using do not smoke.
Wash hands before breaks and at the end of workday.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : capsules

Color : white, light yellow

Odor : Not applicable

Odor Threshold : Not applicable

pH : Not applicable

Melting point/range : No data available

Boiling point/boiling range : No data available

Flash point : does not flash

Evaporation rate : No data available

Flammability (solid, gas) : Not classified as a flammability hazard
Remarks: Expert judgment

Self-ignition : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

ALECENSA® Capsules (150 mg)

Version 1.2 Revision Date: 01-16-2020 Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

Vapor pressure : No data available

Relative vapor density : Not applicable

Relative density : No data available

Solubility(ies)

 Water solubility : No data available

 Solubility in other solvents : No data available

Partition coefficient: n-
octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

 Viscosity, dynamic : Not applicable

 Viscosity, kinematic : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-
tions : No decomposition if stored and applied as directed.

Conditions to avoid : Do not expose to temperatures above: 100 °C
Exposure to moisture.
Exposure to light.

Incompatible materials : No data available

Hazardous decomposition
products : No data available

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 7.85 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:**Alectinib hydrochloride:**

Acute oral toxicity : LD0 (Rat): 2,000 mg/kg
Assessment: The component/mixture is minimally toxic after single ingestion.

Sulfuric acid monododecyl ester sodium salt (1:1):

Acute oral toxicity : LD50 Oral (Rat): 1,200 mg/kg

Acute inhalation toxicity : Assessment: The component/mixture is moderately toxic after short term inhalation.

Acute dermal toxicity : LD50 Dermal (Rat, male and female): > 2,000 mg/kg

Lactose-monohydrate:

Acute oral toxicity : LD50 Oral (Rat): > 10,000 mg/kg

Titanium oxide (TiO₂):

Acute oral toxicity : LD50 (Rat): > 7,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 10,000 mg/kg

Octadecanoic acid, magnesium salt (2:1):

Acute oral toxicity : LD50 Oral (Rat): > 2,000 mg/kg

Skin corrosion/irritation

Causes skin irritation.

Product:

Remarks : May cause skin irritation in susceptible persons.

Components:**Sulfuric acid monododecyl ester sodium salt (1:1):**

Result : Irritating to skin.

Serious eye damage/eye irritation

Causes serious eye damage.

Product:

Remarks : May cause irreversible eye damage.

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017**Components:****Sulfuric acid monododecyl ester sodium salt (1:1):**

Result : Risk of serious damage to eyes.

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:**Alectinib hydrochloride:**Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 487
Result: positiveTest Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 473
Result: negativeTest Type: Ames test
Metabolic activation: with and without metabolic activation
Result: negativeGenotoxicity in vivo : Test Type: In vivo micronucleus test
Application Route: Oral
Method: OECD Test Guideline 474
Result: positive
GLP: yes
Remarks: Not classified due to data which are conclusive
although insufficient for classification.

Germ cell mutagenicity - Assessment : In vitro tests showed mutagenic effects

Carcinogenicity

Suspected of causing cancer.

Components:**Sulfuric acid monododecyl ester sodium salt (1:1):**Remarks : No ingredient of this product present at levels greater than or
equal to 0.1% is identified as probable, possible or confirmed
human carcinogen by IARC.**Lactose-monohydrate:**Remarks : No ingredient of this product present at levels greater than or
equal to 0.1% is identified as probable, possible or confirmed

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

human carcinogen by IARC.

IARC	Group 2B: Possibly carcinogenic to humans Titanium oxide (TiO ₂)	13463-67-7
OSHA	No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.	
NTP	No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.	

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:**Alectinib hydrochloride:**

Effects on fetal development : Species: Rat, females
Application Route: Oral
Dose: 3 mg/kg/d
Duration of Single Treatment: 11 d
GLP: yes
Remarks: NOAEL (No observed adverse effect level)

Species: laboratory animal
Symptoms: Skeletal and visceral variations ., Skeletal malformations.
Result: Effects on fetal development., Fetal growth retardation

Reproductive toxicity - Assessment : Suspected human reproductive toxicant, Suspected of damaging fertility., Suspected of damaging the unborn child.

STOT-single exposure

Not classified based on available information.

Components:**Sulfuric acid monododecyl ester sodium salt (1:1):**

Assessment : May cause respiratory irritation.

Octadecanoic acid, magnesium salt (2:1):

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:**Alectinib hydrochloride:**

Assessment : May cause damage to organs through prolonged or repeated exposure.

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017**Octadecanoic acid, magnesium salt (2:1):**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Aspiration toxicity

Not classified based on available information.

Components:**Octadecanoic acid, magnesium salt (2:1):**

No data available

Further information**Components:****Alectinib hydrochloride:**

Test Type : OECD Test Guideline 432

Remarks : Phototoxic (in vitro)
The value is given in analogy to the following substances: Alectinib

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Alectinib hydrochloride:**Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10 mg/l
End point: mortality
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yes
Remarks: nominal concentrationToxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
GLP: yes
Remarks: nominal concentrationNOEC (Daphnia magna (Water flea)): 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
GLP: yes
Remarks: nominal concentrationToxicity to algae/aquatic plants : ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 11.7 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: average measured concentration

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

EyC50 (Raphidocelis subcapitata (freshwater green alga)): > 11.7 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201
 GLP: yes
 Remarks: average measured concentration

NOEC (Raphidocelis subcapitata (freshwater green alga)): > 11.7 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201
 GLP: yes
 Remarks: average measured concentration

Toxicity to fish (Chronic toxicity) : NOEC (Danio rerio (zebra fish)): 10 mg/l
 Exposure time: 36 d
 Test Type: Fish early-life stage (FELS) toxicity test (OECD 210)
 Analytical monitoring: yes
 Method: OECD Test Guideline 210
 GLP: yes

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.133 mg/l
 End point: Immobilization
 Exposure time: 21 d
 Analytical monitoring: yes
 Method: OECD Test Guideline 211
 GLP: yes

Toxicity to microorganisms : NOEC (activated sludge): 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 GLP: yes
 Remarks: Barely inhibitory on aerobic bacterial respiration

Sulfuric acid monododecyl ester sodium salt (1:1):

Toxicity to fish : LC0 (Leuciscus idus (Golden orfe)): 29 mg/l
 LC50 (Lepomis macrochirus (Bluegill sunfish)): 4.1 mg/l
 Exposure time: 96 h
 LC50 (Oncorhynchus mykiss (rainbow trout)): 3.6 mg/l
 Exposure time: 96 h
 NOEC (Pimephales promelas (fathead minnow)): 1.36 mg/l
 Exposure time: 42 d

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 5.55 mg/l
 Exposure time: 48 h
 NOEC (Ceriodaphnia dubia (water flea)): 0.88 mg/l
 Exposure time: 7 d

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

Toxicity to microorganisms : LC50 (activated sludge): 135 mg/l
Exposure time: 3 h
Test Type: EC50
Method: OECD Test Guideline 209

Ecotoxicology Assessment

Chronic aquatic toxicity : Harmful to aquatic life with long lasting effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Titanium oxide (TiO₂):

Toxicity to fish : LC0 (Leuciscus idus (Golden orfe)): > 1,000 mg/l
Exposure time: 48 h

Toxicity to daphnia and other aquatic invertebrates : EC0 (Daphnia magna (Water flea)): 3 mg/l
Exposure time: 720 h

Ecotoxicology Assessment

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Octadecanoic acid, magnesium salt (2:1):**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Persistence and degradability**Components:****Alectinib hydrochloride:**

Biodegradability : aerobic
Concentration: 46,95 mg/ml
Theoretical oxygen demand
Result: Not readily biodegradable.
Biodegradation: 0 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
GLP: yes

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017**Sulfuric acid monododecyl ester sodium salt (1:1):**

Biodegradability : Biodegradation: 90 %
Exposure time: 28 d
Method: OECD Test Guideline 301
Remarks: Readily biodegradable, according to appropriate OECD test.

Bioaccumulative potential**Components:****Alectinib hydrochloride:**

Bioaccumulation : Species: Danio rerio (zebra fish)
Bioconcentration factor (BCF): 147.7
Exposure time: 32 d
Method: OECD Test Guideline 305
GLP: yes

Partition coefficient: n-octanol/water : log Pow: 3.85
Method: OECD Test Guideline 117
GLP: yes
The value is given in analogy to the following substances:
Alectinib

Sulfuric acid monododecyl ester sodium salt (1:1):

Bioaccumulation : Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 3.9 - 5.3
Exposure time: 3 d

Partition coefficient: n-octanol/water : log Pow: -2.03 (20 °C / 20 °C)
Method: OECD Test Guideline 107

Lactose-monohydrate:

Bioaccumulation : Remarks: No bioaccumulation is to be expected (log Pow <= 4).

Partition coefficient: n-octanol/water : log Pow: -5.03

Titanium oxide (TiO₂):

Partition coefficient: n-octanol/water : Remarks: No data available

Octadecanoic acid, magnesium salt (2:1):

Partition coefficient: n-octanol/water : log Pow: 0.8
Method: OECD Test Guideline 107

Mobility in soil**Components:****Alectinib hydrochloride:**

ALECENSA® Capsules (150 mg)

Version 1.2 Revision Date: 01-16-2020 Date of last issue: 07-27-2018
 Date of first issue: 06-10-2017

Distribution among environmental compartments : Medium: Soil
 Koc: 14921 - 32878 ml/g
 Method: OECD Test Guideline 106
 Remarks: immobile

Medium: Sludge
 Koc: 5707 - 16634 ml/g
 Method: OECD Test Guideline 106
 Remarks: immobile

Medium: Sludge
 Kd: 1,473 - 4,294 ml/g
 Method: OECD Test Guideline 106
 Remarks: immobile

Other adverse effects
Product:

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
 Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Additional ecological information : An environmental hazard cannot be excluded in the event of unprofessional handling or disposal.
 Harmful to aquatic life.
 Toxic to aquatic life with long lasting effects.

Components:
Sulfuric acid monododecyl ester sodium salt (1:1):

Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS
Disposal methods

Waste from residues : The product should not be allowed to enter drains, water courses or the soil.
 Do not contaminate ponds, waterways or ditches with chemical or used container.
 Send to a licensed waste management company.

Contaminated packaging : Empty remaining contents.
 Dispose of as unused product.
 Empty containers should be taken to an approved waste handling site for recycling or disposal.
 Do not re-use empty containers.

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3077
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Alectinib Hydrochloride Mixture)
 Class : 9
 Packing group : III
 Labels : 9

IATA-DGR

UN/ID No. : UN 3077
 Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Alectinib Hydrochloride Mixture)
 Class : 9
 Packing group : III
 Labels :
 Packing instruction (cargo aircraft) : 956
 Packing instruction (passenger aircraft) : 956
 Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Alectinib Hydrochloride Mixture)
 Class : 9
 Packing group : III
 Labels : 9
 EmS Code : F-A, S-F
 Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation**49 CFR**

UN/ID/NA number : UN 3077
 Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Alectinib Hydrochloride Mixture)
 Class : 9
 Packing group : III
 Labels : Class 9 - Miscellaneous dangerous substances and articles
 ERG Code : 171
 Marine pollutant : no

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

ALECENSA® Capsules (150 mg)

Version
1.2

Revision Date:
01-16-2020

Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
SARA 311/312 Hazards	:	Skin corrosion or irritation Serious eye damage or eye irritation Germ cell mutagenicity Carcinogenicity Reproductive toxicity Specific target organ toxicity (single or repeated exposure)

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM I Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

US State Regulations

Massachusetts Right To Know

Titanium oxide (TiO₂) 13463-67-7

Pennsylvania Right To Know

Alectinib hydrochloride 1256589-74-8
 Cellulose, 2-hydroxypropyl methyl ether 9004-65-3
 Sulfuric acid monododecyl ester sodium salt (1:1) 151-21-3
 Cellulose, carboxymethyl ether, calcium salt 9050-04-8
 Lactose-monohydrate 10039-26-6
 Titanium oxide (TiO₂) 13463-67-7

ALECENSA® Capsules (150 mg)

Version
1.2

Revision Date:
01-16-2020

Date of last issue: 07-27-2018
Date of first issue: 06-10-2017

Maine Chemicals of High Concern

Vermont Chemicals of High Concern

Washington Chemicals of High Concern

California Prop. 65

WARNING: This product can expose you to chemicals including Titanium oxide (TiO₂), which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants

Titanium oxide (TiO₂) 13463-67-7

The ingredients of this product are reported in the following inventories:

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Alectinib hydrochloride

non hazardous compounds

Cellulose, carboxymethyl ether, calcium salt

AICS : Not in compliance with the inventory

NZIoC : Not in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory

TCSI : Not in compliance with the inventory


TSCA : Substance(s) not active and not listed on TSCA inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

ALECENSA® Capsules (150 mg)Version
1.2Revision Date:
01-16-2020Date of last issue: 07-27-2018
Date of first issue: 06-10-2017**NFPA:****HMIS® IV:**

HEALTH	*	3
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
OSHA P0	:	USA. OSHA - TABLE Z-1 Limits for Air Contaminants - 1910.1000
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
OSHA P0 / TWA	:	8-hour time weighted average
OSHA Z-1 / TWA	:	8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amend-

ALECENSA® Capsules (150 mg)

Version	Revision Date:	Date of last issue: 07-27-2018
1.2	01-16-2020	Date of first issue: 06-10-2017

ments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

The GHS classification for skin irritation and/or sensitization of the pure ingredients causes a corresponding GHS classification for the whole formulation. In view of the nature of the formulated product (film-coated tablet, capsule, etc.) an over-interpretation of the potential hazard is possible.

Revision Date : 01-16-2020

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 1810